Autophagy in Idiopathic Pulmonary Fibrosis by Lin, Ling et al.
 
Autophagy in Idiopathic Pulmonary Fibrosis
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Patel, Avignat S., Ling Lin, Alexander Geyer, Jeffrey A. Haspel,
Chang Hyeok An, Jiaofei Cao, Ivan O. Rosas, and Danielle Morse.
2012. Autophagy in idiopathic pulmonary fibrosis. PLoS ONE
7(7): e41394.
Published Version doi:10.1371/journal.pone.0041394
Accessed February 19, 2015 10:47:07 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10445569
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAAutophagy in Idiopathic Pulmonary Fibrosis
Avignat S. Patel
1, Ling Lin
2, Alexander Geyer
3, Jeffrey A. Haspel
1, Chang Hyeok An
1, Jiaofei Cao
1,
Ivan O. Rosas
1,4, Danielle Morse
1*
1Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America,
2Department of Medicine, Pennsylvania State University, Hershey, Pennsylvainia, United States of America, 3Division of Pulmonary, Critical Care, and Sleep Medicine, Mt.
Sinai School of Medicine, New York, United States of America, 4Lovelace Respiratory Research Institute, Albuquerque, New Mexico, United States of America
Abstract
Background: Autophagy is a basic cellular homeostatic process important to cell fate decisions under conditions of stress.
Dysregulation of autophagy impacts numerous human diseases including cancer and chronic obstructive lung disease. This
study investigates the role of autophagy in idiopathic pulmonary fibrosis.
Methods: Human lung tissues from patients with IPF were analyzed for autophagy markers and modulating proteins using
western blotting, confocal microscopy and transmission electron microscopy. To study the effects of TGF-b1 on autophagy,
human lung fibroblasts were monitored by fluorescence microscopy and western blotting. In vivo experiments were done
using the bleomycin-induced fibrosis mouse model.
Results: Lung tissues from IPF patients demonstrate evidence of decreased autophagic activity as assessed by LC3, p62
protein expression and immunofluorescence, and numbers of autophagosomes. TGF-b1 inhibits autophagy in fibroblasts in
vitro at least in part via activation of mTORC1; expression of TIGAR is also increased in response to TGF-b1. In the bleomycin
model of pulmonary fibrosis, rapamycin treatment is antifibrotic, and rapamycin also decreases expression of a ´-smooth
muscle actin and fibronectin by fibroblasts in vitro. Inhibition of key regulators of autophagy, LC3 and beclin-1, leads to the
opposite effect on fibroblast expression of a ´-smooth muscle actin and fibronectin.
Conclusion: Autophagy is not induced in pulmonary fibrosis despite activation of pathways known to promote autophagy.
Impairment of autophagy by TGF-b1 may represent a mechanism for the promotion of fibrogenesis in IPF.
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Introduction
Autophagy is a catabolic process by which components of the
cytoplasm are degraded in lysosomes. During this process,
cytoplasmic cargo is sequestered within double-membraned
autophagosomes and then degraded after fusion of autophago-
somes with lysosomes. Although this morphological process was
originally described half a century ago [1], the molecular
mechanisms of autophagy have been only lately described,
leading to recent interest in the role of autophagy in disease.
Autophagy was first understood as a process by which organelles
and macromolecules could be catabolized to remove damaged
structures or to provide energy under conditions of nutrient
starvation. The importance of autophagy to homeostasis and
development has been underscored by numerous studies in yeast
and mice [2,3,4,5]. The function of autophagy in human disease
and pre-clinical models of disease appears to be highly
pleiotropic, however, and it is not always possible to predict
the outcome of interventions that affect autophagy. In some
instances, autophagy has been shown to be an adaptive pro-
survival response, whereas under other circumstances autophagy
appears to promote cell death and morbidity [6,7]. Relatively
few studies have addressed the role of autophagy in the lung;
hence the role of autophagy in adult lung disease remains largely
undefined. Autophagy in chronic obstructive lung disease
(COPD) is greatly enhanced in the epithelium and appears to
precede apoptosis and contribute to progression of disease [8,9].
In alveolar macrophages of COPD patients, however, there is an
impairment in autophagy [10]. In cystic fibrosis, there is evidence
that mutant CFTR protein impairs autophagosome formation
via depletion of beclin-1 [11]. Recently, it was demonstrated that
tumorigenesis in tuberous sclerosis complex (TSC) which includes
pulmonary lymphangioleiomyomatosis (LAM) is autophagy de-
pendent [12], and Mi et.al. found that IL-17 antagonism induces
autophagy and is protective in a mouse model of fibrosis [13].
Whether autophagy influences the outcome of idiopathic
pulmonary fibrosis (IPF), a disease involving multiple cell types
and pathogenic mechanisms, is unknown.
Recent advances in our understanding of the pathogenesis of
IPF have underscored potential links with autophagy. Markers of
ER stress have been shown to be increased in type II alveolar
epithelial cells of IPF lungs compared with COPD or donor
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fibrosis in experimental models [15]. ER stress is also known to
induce autophagy [16], promoting cell survival [17] or death [18]
in a context-specific manner. Markers of oxidative stress have also
been identified in the lungs of IPF patients [19], and recent studies
indicate that oxidative stress or elevated reactive oxygen species
activate autophagy [20,21]. Autophagy is also sensitive to oxygen
tension and the hypoxia-inducible factor (HIF)-1a has been
implicated as a major regulator of autophagy under hypoxic
conditions [22]. Levels of HIF-1a are elevated in pulmonary
fibrosis [23] and may contribute to disease progression [24,25].
These associations suggest that autophagy is likely to be induced in
pulmonary fibrosis. In this study, we used human tissues, the
murine bleomycin model and an in vitro transforming growth
factor-b1 (TGF-b1) model to explore the relationship of autophagy
to fibrosis.
Results
Autophagy is not increased in IPF
An immunoblot for X-box binding protein 1 (XBP1), a pivotal
gene in the endoplasmic reticulum (ER) stress response, is shown
in figure 1A. This immunoblot confirms previously published
findings that ER stress is elevated in IPF lungs relative to control
lungs [14], which would be expected to lead to increased levels of
autophagy [16,17]. Similarly, levels of phosphorylated AMPK
(pAMPK) are higher in IPF lung than control lungs (figure 1A).
AMPK activation is a well known trigger of autophagy [26] and
is phosphorylated in situations where ATP synthesis is decreased
(hypoxia, ischemia, low nutrient availability) or ATP consump-
tion is increased. Despite evidence of ER stress and AMPK
activation, we show in figure 1B and 1C that LC3-II levels are
significantly lower in whole tissue homogenate of lungs from
patients with IPF compared with control lungs from transplant
donors without IPF. LC3, otherwise known as ‘‘microtubule-
associated protein 1 light chain 3’’, or MAP1LC3, is commonly
used to monitor autophagy in cultured cells and animal tissue.
The cytosolic form of LC3 (termed LC3-I) is seen as the upper
band in the immunoblot, and the autophagosomal membrane
lipidated form (termed LC3-II) makes up the lower band [27].
We also show in figure 1D that p62 protein levels are higher in
IPF than in control lung tissue. Levels of p62 (a chaperone
molecule that carries cargo to the autophagosome for selective
degradation) inversely correlate with autophagic activity [28]. We
also assessed p62 levels by immunofluorescence confocal
microscopy (Fig. 1E) and found higher amounts of p62 in IPF
tissue than control, confirming the Western blot findings.
Electron microscopy (EM), the gold standard for identification
of autophagosomes, supports the Western blot and immunoflu-
orescence results. In contrast to lungs of patients with COPD,
which have previously been shown to exhibit elevated levels of
autophagy [8], lungs from patients with IPF demonstrate only
rare autophagosomes. This is shown in figure 1F panel D, where
numerous autophagosomes in lung from a patient with COPD
are labeled with white arrows; in contrast, few or no
autophagosomes are seen in IPF (panel A, B) and control (Panel
C) samples. Quantitation of autophagosome numbers is shown in
figure 1G. Taken together, these data indicate that autophagy is
not induced in lungs of patients with IPF despite activation of
pathways known to increase levels of tissue autophagy.
TGF-b1 inhibits autophagy in vitro
TGF-b1 is an essential mediator of fibrosis through its effects
on fibroblasts [29], epithelial cells [30] and other cells of the
lung. In order to test whether TGF-b1 would affect autophagy,
we tested its effect on fibroblast cell lines in vitro. As shown in
figure 2A, TGF-b1 inhibits conversion of LC3-I to LC3-II in
a human lung fibroblast cell line in a dose-dependent manner in
response to serum starvation. We also tested varying concentra-
tions of serum from 0–2% and time points up to 48 hours and
found the same effect (figure 2C), along with increased p62 levels
implying reduced autophagy (figure 2B). To validate these
conclusions we directly examined the effect of TGF-b1 on
autophagic activity (or flux), as reflected by the turnover of LC3
in lysosomes [28]. For this experiment, fibroblasts were treated
with 25 mM chloroquine or PBS 2 hours prior to harvest. The
result was consistent with static LC3 levels, showing decreased
flux (or LC3 turnover) in response to TGF-b1 (figure 2D, E). The
images in figure 2F demonstrate the accumulation of punctate
foci of green fluorescent protein (GFP) after starvation of
fibroblasts transfected with a GFP-LC3 construct. The puncta
are thought to represent autophagosomes [31], and therefore the
paucity of puncta in the presence of TGF-b1 confirm a lower
level of autophagy. Figure 2G represents GFP puncta formation
in type II alveolar epithelial cells isolated from GFP-LC3
transgenic mice [27]. Similar to the effect seen in fibroblasts,
TGF-b1 inhibits puncta formation in these epithelial cells
confirming fewer autophagosomes (figure 2H).
Inhibition of mTORC1 by rapamycin leads to
improvement in bleomycin-induced experimental
fibrosis
Since one of the primary modulators of autophagy is the
mTORC1 pathway, we tested whether differences in the level of
mTORC1 activity would affect the development of lung fibrosis in
the murine bleomycin model by using the mTORC1 inhibitor
rapamycin. We treated mice with oral rapamycin five days per
week for 3 weeks following intratracheal bleomycin instillation. As
shown in figure 3, mice receiving rapamycin in addition to
bleomycin had significantly lower levels of lung hydroxyproline as
a measure of collagen content than mice treated with bleomycin
alone (97.3 vs 129.0 mcg/lung, p=0.008).
TGF-b1 activates mTORC1 and TIGAR
Since mTORC1 inhibition and autophagy induction in the
murine bleomycin model decreased fibrosis and TGF-b1 de-
creased autophagy, we hypothesized that TGF-b1 might inhibit
autophagy via activation of phosphatidylinositol-3-kinase (PI3K),
Akt and mTORC1. Glucose-induced cell hypertrophy was also
recently shown to involve TGF-b1 activation of the Akt-TOR
pathway [32]. We therefore tested whether rapamycin is able to
overcome TGF-b1 suppression of LC3 activation. As a negative
control, we used interferon-c to induce autophagy via a non-
mTORC1 pathway. (Interferon is thought to induce autophagy
via the immunity-related GTPase family M protein IRGM
[33,34]). As shown in figure 4A and B, TGF-b1 is capable of
inhibiting autophagy in the presence of interferon-c, but not in
the presence of rapamycin. To explore this further, we examined
the effect of TGF-b1 on phosphorylation of the S6 ribosomal
protein. S6 ribosomal protein is phosphorylated by p70-S6
Kinase 1 (S6K1), which in turn is one of the most well-known
targets of mTORC1. S6 phosphorylation is therefore commonly
used to monitor mTORC1 activation [35]. As expected,
rapamycin treatment resulted in inhibition of p-S6 (figure 4C).
Starvation also led to a time-dependent decrease in p-S6 which
was partially reversed by the addition of TGF-b1. Rapamycin
fully inhibited the effect of TGF-b1 on S6 phosphorylation. The
Autophagy in IPF
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response to TGF-b1 and also resulted in decreased ribosomal
protein S6 phosphorylation (figure 4D). TGF-b1 also induces
phosphorylation of mTOR at Ser2448 which has been theorized
to correlate with mTOR activation (Figure 4E). To assess
whether mTORC1 activity is increased in the setting of
experimental lung fibrosis, mice were treated with intratracheal
bleomycin alone or bleomycin and oral rapamycin 5 days per
week. Lungs were assayed for S6 phosphorylation 3 weeks after
initiation of treatment. As shown in figure 4F (and by
densitometry in 4G), bleomycin treatment resulted in a significant
increase in p-S6; as expected, this was abrogated by concomitant
treatment with rapamycin. We then analyzed human lung tissue
for p-S6 and found that on average, IPF patient samples have
increased p-S6 expression compared to controls and COPD
(figure 4H), but the phosphorylation is not uniform among the
samples.
Another more recently described modulator of autophagy is
TIGAR, or tp53-induced glycolysis and apoptosis regulator. The
p53-inducible TIGAR protein functions as a fructose-2,6-bispho-
sphatase, promoting the pentose phosphate pathway. Expression
of TIGAR has been shown to inhibit autophagy, via a mechanism
thought to involve modulation of intracellular reactive oxygen
species (ROS) [36,37]. In figure 4I, we demonstrate that TGF-b1 is
able to induce TIGAR expression under serum starvation in
a dose-responsive manner. In addition, we examined TIGAR
protein expression in human lung homogenate from control,
COPD, and IPF patient samples (figure 4J). This shows that
TIGAR is increased in IPF compared with controls and COPD.
Therefore, TGF-b1 induction of TIGAR may be another
mechanism by which autophagic activity is modulated.
Inhibition of autophagy increases a-smooth muscle actin
and fibronectin expression in fibroblasts
The effect of rapamycin on fibroblast matrix production has
been examined by other investigators. Rapamycin does not appear
to directly affect activation of Smad signaling or transcription of
collagen-1; conflicting data exist as to whether rapamycin can
inhibit collagen-1 production through post-translational mechan-
isms [38–39]. Rapamycin has been reported to slow anchorage-
independent fibroblast growth and lessen TGF-b–mediated
myofibroblast morphologic transformation and extracellular ma-
trix synthesis [39,40]. In keeping with these findings, we show in
figure 5A that rapamycin treatment decreases fibroblast a-smooth
muscle actin (a-SMA) and fibronectin expression in response to
TGF-b1 and prevents suppression of the cytostatic inhibitor of
differentiation-1 (Id1) [41] by TGF-b1. The expression of collagen-
1 is unaffected by rapamycin treatment. We then tested whether
inhibition of the progression of autophagy itself would affect
fibroblast responses to TGF-b1. In order to inhibit autophagy,
fibroblasts were treated with siRNA specific for either beclin
(Becn1) or LC3 prior to TGF-b1 exposure (figure 5B). In-
terestingly, inhibition of either Becn1 or LC3 led to enhanced
fibronectin and a -SMA expression in response to TGF-b1
(figure 5C). Expression of collagen-1 was unchanged by siRNA
treatment. We also tested whether LC3 inhibition would affect
levels of Id1, the absence of which has been shown to potentiate
fibrosis [42]. As shown in figure 5D, Id1 expression was markedly
lower in fibroblasts treated with LC3 siRNA than in control
Figure 1. Autophagy is not increased in IPF. A) IPF whole lung homogenate demonstrates increased ER stress (elevated XBP1 expression) and
increased phosphorylation of AMPK, factors which should drive autophagy. B) LC3-II (lower band) expression in IPF whole lung homogenate is
decreased relative to control lung tissue C) Densitometry of Western blots demonstrating LC3-II level is lower in IPF than in control lung (*p=0.05). D)
Increased p62 in IPF lung suggests decreased autophagy. E) Immunofluorescence confocal microscopy of control and IPF lung tissue for p62 (green),
aggresome (red), DAPI (blue) demonstrates increased p62 expression and aggresomes. F) Representative electron microscopy images from IPF
(panels A, B), control (Panel C), and COPD (panel D); white arrows indicate autophagosomes. G) Quantitation of autophagic vacuoles in control, IPF,
and COPD lung by EM demonstrates significantly higher numbers in COPD (*p,0.05 for IPF vs. COPD).
doi:10.1371/journal.pone.0041394.g001
Autophagy in IPF
PLoS ONE | www.plosone.org 3 July 2012 | Volume 7 | Issue 7 | e41394Figure 2. TGF-b1 inhibits autophagy in vitro. A) Human lung fibroblasts were cultured and treated with varying concentrations of TGF-b1. TGF-b1
inhibited activation of LC3, decreasing the intensity of the lower band on the western blot, and B) increased p62. C) Inhibition of LC3 activation by
TGF-b1 with varying serum conditions. D) Fibroblasts treated with TGF-b1 for 24 hours and measurement of autophagic flux by LC3 western blotting
(using lysosomal acidification inhibitor chloroquine). E) Densitometry of western blot shown in D (p=0.045). F) Fluorescence microscopy of
fibroblasts transfected with GFP-LC3 construct and stimulated with TGF-b1 showing that TGF-b1 inhibits formation of LC3 puncta. G) Confocal
microscopy of type II alveolar epithelial cells isolated from GFP-LC3 transgenic mice and stimulated with TGF-b1 showing that TGF-b1 inhibits
formation of LC3 puncta (green=GFP-LC3, red=SP-C, blue=DAPI). H) Quantification of GFP puncta per cell from figure 2G.
doi:10.1371/journal.pone.0041394.g002
Autophagy in IPF
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Western blotting on fibroblasts treated with TGF-b1 with and
without rapamycin. This shows the expected induction of p-
Smad3 with TGF-b1 but no change with rapamycin.
Discussion
Our findings provide evidence that autophagy is not activated in
the setting of IPF despite well described elevations in (ER) stress
[14,15], oxidative stress [19], and (HIF)-1a [23], which are all
known to induce autophagy. We have shown that TGF-b1 inhibits
autophagy in fibroblasts in vitro, and it is therefore possible that
elevated TGF-b1 activity in the IPF lung accounts for this
disconnect. Our studies using inhibitors of mTORC1 and PI3K
suggest that the effect of TGF-b1 on autophagy is mediated at least
in part via activation of PI3K, Akt and mTORC1, although the
increased expression of TIGAR we observed may also play a role.
In the bleomycin model of pulmonary fibrosis, administration of
rapamycin, an inducer of autophagy [43], significantly reduced the
Figure 3. Effects of rapamycin on bleomycin induced fibrosis
and autophagy. Hydroxyproline assay measuring lung collagen
content demonstrates co-administration of rapamycin and bleomycin
protects against fibrosis (*p=0.003 for control vs. bleomycin;
**p=0.008 for bleomycin vs. rapamycin + bleomycin).
doi:10.1371/journal.pone.0041394.g003
Figure 4. TGF-b1 activates mTOR and TIGAR. A) In human lung fibroblasts, TGF-b1 inhibits LC3-II formation, even in the presence of IFN-c which
induces autophagy. B) TGF-b1 is unable to inhibit LC3-II formation in presence of mTOR inhibitor rapamycin. C) TGF-b1 is able to activate mTORC1
which results in increased phospho-S6 but this activation does not occur in the presence of rapamycin. D) TGF-b1 appears to activate mTORC1 by
activating upstream PI3K/AKT and treatment with PI3K inhibitor LY294002 prevents TGF-b1 induced mTOR activation. E) Western blot of phospho-
mTOR (Ser2448) showing increased phospho-mTOR with TGF-b1 in fibroblasts and inhibition by rapamycin. F) Western blot of phospho-S6 from
mouse lung tissue treated with bleomycin and rapamycin. G) Densitometry of blot from 4E. (*p=0.03 for controls vs. bleomycin, **p=0.003 for
bleomycin vs rapamycin + bleomycin). H) phospho-S6 protein levels in human lung tissue is higher in IPF patients compared with COPD patients and
healthy controls. I) TIGAR is induced by TGF-b1 in fibroblasts in a dose-responsive manner. J) Western blot demonstrating TIGAR protein levels in lung
homogenate from human tissue is higher in IPF patients compared with COPD patients and healthy controls.
doi:10.1371/journal.pone.0041394.g004
Autophagy in IPF
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a previous study using a TGF-a overexpression model of
pulmonary fibrosis; rapamycin was also shown to have a protective
effect against fibrosis [44]. Other studies evaluating rapamycin in
a rat bleomycin model and a murine systemic sclerosis model have
discovered similar anti-fibrotic effects [45,46,47]. Finally, we have
shown that inhibition of autophagic proteins LC3 and Beclin-1
leads to increased a-SMA and fibronectin expression by fibroblasts
in response to TGF-b1, and that rapamycin has the opposite effect.
One of the main questions raised by this study is the mechanism
by which autophagy modulates matrix and a ´-SMA expression. As
autophagy represents a protein degradation pathway, it is
reasonable to speculate that autophagy serves to degrade matrix
molecules like fibronectin intracellularly before they are secreted.
In a recent study by Arranguiz-Urroz, et.al.[48], the authors
demonstrated that b2 adrenergic receptor agonism in cardiac
fibroblasts activates autophagy leading to increased intracellular
degradation of collagen. Another study demonstrated rapamycin
decreases both fibronectin and collagen protein levels without
affecting transcription [40]. More recently, Mi, et.al. showed that
IL-17A antagonism protects against fibrosis by inducing autop-
hagy and enhancing collagen degradation in epithelial cells [13].
In mouse mesangial cells, it has been shown that disruption of
beclin-1 leads to collagen accumulation, both at baseline and with
TGF-b1 stimulation [49]. In that study, induction of autophagy
also led to intracellular collagen degradation. In contrast to our
findings, however, TGF-b1 stimulated autophagy in mesangial
cells, which may be due to differences in cell type and organ.
Although we did not explore the dynamics of collagen turnover in
the present study, our results do not indicate large differences in
collagen-1 expression in response to LC3 and Beclin-1 inhibition
or to treatment with rapamycin in lung fibroblasts. This is
consistent with a previous study that also showed that rapamycin
lessens TGF-b–mediated myofibroblast morphologic transforma-
tion without greatly affecting collagen production [39]. These
findings, coupled with the fact that most extracellular matrix
protein degradation does not occur intracellularly, indicate that
this mechanism may not account entirely for the effect of
autophagy on fibrosis.
Another potential explanation for the mechanism by which
autophagy affects fibroblasts is a yet undescribed interaction
between autophagy and TGF-b1 signaling pathways, either Smad-
dependent or independent. Our data demonstrating that autop-
hagy also affects Id-1 levels support this mechanism because Id1 is
known to be both a target and modulator of Smad signaling [42]
[41]. Despite this, we did not find a difference in phosphorylated
Smad3 in cells treated with TGF-b1 and rapamycin. Thus, an
alternative element of the Smad signaling pathway may be
involved or a Smad-independent mechanism may account for the
effects of autophagy on fibroblasts. The nature of any interaction
between TGF-b1 signaling and autophagy will need to be further
investigated in future studies.
The relationship between ER stress and IPF have been
highlighted by a number of investigators [14,15], and this
represents another mechanism by which increased autophagy
could be anti-fibrotic. Besides being potently induced by ER stress
[50], autophagy is thought to play a vital role in clearing
intracellular protein aggregates, thus modulating cell survival
during the unfolded protein response [50]. While epithelial ER
stress in IPF is thought to be due to misfolding of aberrant proteins
rather than defective clearance [51], it may be that the lack of
autophagy exacerbates this process. Increased accumulation of
protein aggregates in the absence of autophagy could worsen ER
stress and promote epithelial cell death.
The demonstration of opposite effects of rapamycin treatment
and inhibition of LC3 or Beclin-1 suggests that rapamycin exerts
its effects on fibroblasts by modulating autophagy but by no means
proves this point. mTORC1 also has well-described key homeo-
static functions as a regulator of protein and lipid biosynthesis, cell
growth, and energy metabolism [52]. Inhibition of these essential
functions of mTORC1 by rapamycin, apart from the drug’s
induction of autophagy, could affect fibroblast differentiation,
matrix production and the development of fibrosis in vivo. This
alternative mechanism could involve suppression of TGF-b1
signaling via mTORC1 or it could be completely independent
of TGF-b1. There are inconsistencies in the literature with regard
to the role of mTORC1 in TGF-b1 induced fibroblast responses.
Goc, et.al. showed that ECM synthesis is inhibited in Akt12/2
Figure 5. Inhibition of autophagy potentiates fibroblast activation. A) Rapamycin inhibits fibronectin and a-SMA expression in fibroblasts,
and abrogates TGF-b1 suppression of Id-1. B) Beclin and LC3 siRNA effectively inhibit protein expression. C) a-SMA and fibronectin expression
increases in fibroblasts with beclin and LC3 silencing whereas collagen is unchanged. D) When LC3 is silenced, Id-1 expression is lower than control. E)
Rapamycin does not modulate phosphorylation of Smad3 in response to TGF-b1.
doi:10.1371/journal.pone.0041394.g005
Autophagy in IPF
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[40]. In contrast, Rahimi, et.al. found that rapamycin did not alter
fibronectin or collagen transcript or protein levels despite evidence
that TGF-b1 activates mTORC1 resulting in increased pro-
liferation [39]. These studies do not address whether any of
rapamycin’s effects can be specifically attributed to autophagy
induction. The ability to induce autophagy in experimental
systems via an mTORC1 independent pathway would help
differentiate mTORC1’s various functions, but this remains
a challenge for the field. Although chemicals and drugs have
been shown to induce autophagy independent of mTORC1, (e.g.
amiodarone, clonidine, calcium channel antagonists), they often
need to be combined with mTOR inhibitors to achieve significant
modulation of autophagy [28]. The results of our experiments
using LC3 and Beclin-1 silencing support the idea that specifically
inhibiting autophagy (without changing mTORC1 activity) can
alter fibroblast responses to TGF-b1. However, more definitive
studies will be required to explore mTORC1 dependent and
independent methods of activating autophagy and the effects they
have on fibrogenesis. Future experiments examining mice with
genetically deficient autophagy may help to address whether
induction of autophagy is required for the antifibrotic effect of
rapamycin.
Another limitation of our study is the use of serum-starvation for
induction of autophagy in vitro. We acknowledge that induction of
autophagy through serum starvation is not reflective of conditions
in human disease. However, to demonstrate TGF-b1’s inhibitory
effect we required the presence of a detectable level of basal
autophagy. Therefore, despite its limitations, we used the most
commonly employed method of accomplishing this. In addition, it
is worth noting that a vast literature on TGF-b1 biological effects
has been generated using serum-starved cell lines. It is interesting
to consider whether artificially low mTORC1 activity and elevated
levels of autophagy in ‘‘control’’ cells has impacted our in-
terpretation of decades of in vitro TGF-b1 studies.
Investigations into the role of autophagy in lung diseases have
been growing over the last several years, and there is now strong
evidence of its impact in COPD and LAM pathogenesis [8,10,12].
In cystic fibrosis, there is evidence that mutant CFTR protein
impairs autophagosome formation via depletion of beclin-1 [11].
Because mutant CFTR is also cleared by autophagosomes [53],
this creates a cycle in which dysfunctional CFTR accumulates
inside the cell. Our study begins another chapter in the emerging
story of autophagy in human lung diseases by investigating its
function in pulmonary fibrosis. Since there are existing drugs that
induce autophagy, this line of investigation offers the possibility of
translation to patient care.
In conclusion, this study demonstrates that autophagy is not
induced in idiopathic pulmonary fibrosis despite the upregulation
of several activators of autophagy. In vitro experiments demonstrate
that the pro-fibrotic mediator, TGF-b1, is likely responsible for
decreased autophagy. Treatment of animals with an autophagy-
inducing agent partially protects against fibrosis. Lastly, we have
demonstrated that inhibition of autophagy promotes extracellular
matrix production by fibroblasts, providing one mechanism by
which autophagy can impact fibrogenesis.
Materials and Methods
Ethics Statement
This study involves the analysis of human clinical samples. All
human lung tissues were obtained from either lung transplantation
explant tissues or from lung resection from thoracic surgical cases.
Lung tissue procurement was completed under clinical protocols
99-H-0068 and/or 04-H-0211, which were approved by the
National Heart, Lung, and Blood Institute Institutional Review
Board. Informed written consent was obtained from all study
participants. All animals were housed in accordance with guide-
lines from the American Association for Laboratory Animal Care.
Protocols were approved with Institutional Animal Use and Care
Committee of Brigham & Women’s Hospital and Harvard
Medical School (Protocol #04551). All experiments were carried
out in a manner to minimize suffering.
Human Subjects
A diagnosis of usual interstitial pneumonia (UIP) was confirmed
by a lung pathologist in all IPF cases. These lung sections were
processed immediately after being obtained from thoracic
surgeons. The isolated lung tissues were snap frozen and stored
at 280uC at the core facility at the Thoracic Center of Excellence
(COE) in Anatomic Pathology at the University of Pittsburgh or
the Pulmonary and Critical Care Branch of Division of Intramural
Research at the National, Heart, Lung and Blood Institute in
Bethesda, Maryland.
Transmission Electron Microscopy and Fluorescence
Microscopy
Lung tissue sections were fixed in formalin and embedded in
paraffin. Tissues or cells were photographed using a JEOL JEM
1210 transmission electron microscope (JEOL, Peabody, MA) at
80 or 60 kV onto electron microscope film (ESTAR thick base;
Kodak, Rochester, NY) and printed onto photographic paper.
Immunofluorescence on human lung tissue sections was per-
formed with p62 (Sigma)/AlexaFluor 647 (Invitrogen), ProteoStat
Aggresome Detection Reagent (Enzo LifeSciences), Hoechst
33343 nuclear stain (Enzo LifeSciences) and images were taken
and processed with Olympus FluoView FV1000 confocal micro-
scope. To examine the distribution of GFP-LC3 in fibroblasts, cells
were observed under a fluorescence microscope and digital images
were acquired for analysis (SPOT, Diagnostic Instruments, Inc.).
To examine GFP-LC3 in the type II alveolar epithelial cells
isolated from mouse lung, images were taken and processed with
Olympus FluoView FV1000 confocal microscope and GFP puncta
were quantified using ImageJ.
Cell Culture, small interfering RNA (siRNA), and GFP-LC3
transfections
Human lung fibroblast MRC-5 cells (ATCC, Manassas, VA)
were maintained in DMEM (Invitrogen, Carslbad, CA) with 10%
fetal bovine serum and 1x penicillin/streptomycin (Invitrogen).
Cells were incubated at 37uC with 5% CO2. 12 hours prior to
treatment, media was changed to low-serum (0.5% FBS). Cells
were then treated with 5 ng/mL recombinant TGF-b1 (Sigma-
Aldrich T7039, St. Louis, MO) for 24h unless otherwise shown.
For certain experiments, the cells were also cotreated with
interferon-c, LY294002, or rapamycin (1 mM). In autophagic flux
assays, the cells were additionally treated with 25 mM chloroquine
(Sigma) for 2h prior to harvest. For siRNAs, LC3 and Beclin
siRNAs (SantaCruz Biotechnology, Santa Cruz, CA) were
transfected according to manufacturer’s protocol. One to two
mg of GFP-LC3 (rat) was transfected into 26105 cells using
Lipofectamine 2000 according to the supplier’s protocol (Invitro-
gen 11668). For isolation of type II alveolar epithelial cells, two 6–
8 week old GFP-LC3 transgenic mice (RIKEN BioResource
Center, RBRC00806, Japan) were sacrificed. Their lungs were
digested in dispase followed by negative selection process to
remove macrophages and fibroblasts. The remaining cells were
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The cells were then fixed in 4% PFA and co-stained with SP-C
(Santa Cruz Biotechnology) and DAPI.
Animal Model
C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME) were
treated with 0.075U of intratracheal bleomycin sulfate (Hospira,
Inc, Lake Forest, IL) on day 1. A subset of mice were also treated
with 50 mg rapamycin (Rapamune solution, Wyeth Pharm., now
Pfizer, NY, NY) by oral gavage 5 days per week beginning at day
0 until lung harvest. The mice were sacrificed and lungs harvested
on Day 24 and snap frozen in liquid nitrogen followed by storage
at 280uC.
Hydroxyproline Assay
The left lung from each animal was dried in a Speed-Vac for
12h, followed by 12 hours hydrolysis in 6N HCL at 110uC. The
hydroylizate was then separated from particulate matter by
centrifugation and neutralized with equivolume 6N NaOH. 15ml
of each sample was then incubated with 100ml Chloramine-T
solution [0.564g chloramine-T (Sigma C-9887), 4ml n-propanol,
32mL Citrate/Acetate Buffer] at room temperature for 20 min,
followed by incubation with 100ml Ehrlich’s Solution [4.5g DMAB
(Sigma D2004), 18.6 mL n-propanol, 7.8 mL perchloric acid] at
65uC for 10 min. OD 550 was read and hyrdroxyproline
concentrations calculated from standard curve generated using
known concentrations of trans-4- hydroxyl-L-proline (Sigma
H5534).
Western Blotting
Western blot analysis was performed using protein extracted
(using RIPA buffer, protease and phosphatase inhibitor cocktail)
from lung homogenate or cell lysate using 4 to 20% Tris-glycine
SDS-PAGE gels (Bio-Rad, Hercules, CA). Primary antibodies
used were phosphoS6, phospho-AKT (Ser473), mTOR, phospho-
mTOR (Ser2448), Smad3, phospho-Smad3 (Cell Signaling
Technology, Beverly, MA), LC3B, b-Actin, p62 (Sigma), a-SMA
(SantaCruz Biotechnology), TIGAR (Abcam, Cambridge, MA).
The secondary antibodies were a goat anti-rabbit or goat anti-
mouse horseradish peroxidase-conjugated antibody (SantaCruz
Biotechnology).
Statistical analysis
Results were expressed as means 6 SD from at least three
independent experiments. Differences in measured variables
between experimental and control group were assessed by using
the Student’s t test. Statistically significant difference was accepted
at P,0.05.
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